CS
HARP

Candriam SCA’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Candriam SCA’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-79,269
Closed -$769K – 897
2022
Q3 		$769K Hold
79,269
– – 0.01% 765
2022
Q2 		$1.51M Hold
79,269
– – 0.01% 558
2022
Q1 		$3.94M Sell
79,269
-1,688
-2% -$87.5K 0.03% 398
2021
Q4 		$6.11M Buy
80,957
+32,006
+65% +$2.18M 0.04% 322
2021
Q3 		$3.87M Hold
48,951
– – 0.03% 446
2021
Q2 		$6.79M Buy
48,951
+48,948
+1,631,600% +$9.34M 0.05% 348
2021
Q1 		$1K Buy
+3
New +$601 ﹤0.01% 805

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Candriam SCA's HARP Position: Q4 2022 in Review

Candriam SCA sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2022, closing a stake of 79,269 shares — an estimated $769K sold.

Candriam SCA first reported a position in HARP in Q1 2021 and held it in 7 quarters. The position peaked at $6.79M in Q2 2021. 49 funds tracked by Wall St. Rank hold HARP as of Q4 2022.

  • Candriam SCA reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Candriam SCA sold 79,269 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $769K.
  • Candriam SCA first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Candriam SCA's Harpoon Therapeutics, Inc. Common Stock position peaked at $6.79M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.